The Future of Drug Pricing
From the Inflation Reduction Act's Medicare negotiation authority to cell therapies priced at millions of dollars, the landscape of drug pricing is shifting. This guide surveys the forces reshaping how medications are priced and accessed.
The Inflation Reduction Act: A Turning Point
The Inflation Reduction Act (IRA), signed into law in August 2022, represents the most significant structural change to US prescription drugPrescription Drug A medication that legally requires a healthcare provider's prescription before dispensing. Prescription-only status is assigned when a drug's risks require professional supervision — due to side effec
The initial scope is limited: 10 drugs were subject to negotiation for 2026 prices, expanding to 15 additional drugs for 2027, and growing further in subsequent years. Only drugs that have been on the market for a minimum number of years without generic or biosimilarBiosimilar A biologic drug that is highly similar to an already approved reference biologic product, with no clinically meaningful differences in safety, purity, or potencyPotency The amount of drug needed to produce a given effect. A more potent drug achieves the same effect at a lower dose. Potency is different from efficacy — a drug can be highly potent but have limited maxi
The first set of negotiated prices — announced in 2024 — showed reductions of 38% to 79% below list price for drugs including blood thinners, diabetes medications, and heart failure treatments. These negotiated prices apply to Medicare Part D beneficiaries beginning in 2026.
The pharmaceutical industry challenged the IRA negotiation provisions in court, arguing that mandatory negotiation constitutes a taking of private property and violates First Amendment commercial speech rights. These challenges have largely been rejected, but litigation continues and the long-term legal stability of the provision remains uncertain.
What is clear is that the principle of federal negotiation — once considered politically impossible in the US — has been established, and the scope of negotiation authority is likely to expand in future legislation regardless of which party controls Congress.
Value-Based Pricing Models
A growing number of payers, manufacturers, and health systems are exploring value-based pricing arrangements — pricing structures that tie the price of a drug to the clinical outcome it achieves. The theory is elegant: manufacturers capture more revenue if their drug works well, and payers bear less risk when outcomes are uncertain.
In practice, value-based arrangements face significant implementation challenges:
- Outcome definition: What counts as success? Outcome metrics must be pre-specified, measurable, and attributable to the drug rather than other factors.
- Time horizon: Many chronic disease outcomes take years or decades to observe. Payers need shorter-term surrogate endpoints.
- Attribution: When a patient takes five medications, which one deserves credit (or blame) for an outcome?
- Administrative complexity: Tracking individual patient outcomes, reconciling payments, and managing refund mechanisms requires infrastructure that most payers lack.
Despite these challenges, outcomes-based agreements have been executed for several drugs, including cholesterol-lowering PCSK9 inhibitors and a multiple sclerosis therapy. As electronic health record data and real-world evidence methodologies improve, value-based arrangements are expected to become more common.
Gene and Cell Therapies: Pricing at a New Scale
The pharmaceutical pricing debates of the past — about $50,000-per-year specialty biologics — may seem modest compared to the pricing landscape emerging for gene and cell therapies. Several approved products in this category have been priced in the range of $1 million to $4.25 million for a single treatment.
Examples include:
- Hemgenix (etranacogene dezaparvovec): An AAV-based gene therapy for hemophilia B, priced at approximately $3.5 million per treatment.
- Zynteglo (betibeglogene spartoctucel): Gene therapy for transfusion-dependent beta-thalassemia, at approximately $2.8 million.
- Skysona (elivaldogene autotemcel): For early cerebral adrenoleukodystrophy, at approximately $3 million.
- Casgevy (exagamglogene autotemcel): A CRISPR-based therapy for sickle cell disease, at approximately $2.2 million.
These prices reflect the extraordinary development cost, the potential for curative or long-duration benefit in severe diseases, and the small patient populations. But they create immediate and severe access challenges. Most insurers lack frameworks for paying multi-million-dollar one-time treatments, creating complex negotiations and sometimes causing patients to go without therapy.
Novel financing models are being developed: installment payments spread over years, outcomes-based payments tied to duration of benefit, and reinsurance pools to spread catastrophic risk across payers. These mechanisms are still evolving.
Outcomes-Based Contracts
Beyond individual value-based pricing deals, outcomes-based contracts at scale are emerging as a structural mechanism for managing uncertainty in high-cost drug pricing. Under these arrangements, manufacturers agree to refund a portion of the drug cost — or provide additional doses — if the drug does not achieve specified outcomes in real-world patient populations.
The Institute for Clinical and Economic Review (ICER) has developed frameworks for cost-effectiveness analysis (measuring the cost per quality-adjusted life year, or QALY) that inform outcomes-based pricing discussions. While the US has been resistant to explicit QALY-based rationing used in other countries' health technology assessment, ICER analyses increasingly influence payer negotiations and formulary decisions.
Outcomes-based contracting for cancer drugs is particularly active. For therapies with uncertain durability of response, payers can negotiate milestone-based payment structures that limit exposure if the drug's benefit is shorter-lived than hoped.
Biosimilar Competition Accelerating
The expiration of patents on major biologic drugs through the late 2020s will bring a wave of biosimilar competition that has the potential to reshape spending on the most expensive therapeutic categories.
Humira (adalimumab), the world's best-selling drug for over a decade, lost patent exclusivity in 2023. By mid-2024, over a dozen biosimilars were on the US market, with some priced at 80–85% below Humira's list price. Market uptake has been slower than in Europe — where biosimilar adoption for Humira exceeded 80% of market share quickly — partly due to rebate contract structures that create incentives to maintain Humira on formulary. But the trajectory toward greater biosimilar uptake is clear.
Biologics for cancer, inflammatory disease, and ophthalmology face similar patent cliffs in the coming years. Analysts project that biosimilar competition will reduce US drug spending by hundreds of billions of dollars cumulatively over the coming decade.
AI and the Cost of Drug Discovery
Artificial intelligence is being applied across every stage of drug discovery: target identification, molecular design, virtual screening, toxicity prediction, and clinical trial optimization. Early applications have already produced several AI-assisted drug candidates that have entered clinical trials.
The implications for pricing are genuinely uncertain. If AI significantly compresses the cost and time of drug discovery — reducing the $1–2 billion average development cost and 10–15 year timeline — the economic justification for high prices based on R&D cost recovery weakens. Manufacturers might argue that AI-enabled drugs should be priced on value rather than cost, preserving high prices. Payers and policymakers may counter that lower development costs should translate to lower prices.
AI also holds potential for more precise patient selection — identifying which patients are most likely to respond to a treatment — which could simultaneously improve real-world effectiveness and reduce the size of clinical trials needed for approval.
International Reference Pricing
Several legislative proposals have called for the US to limit domestic drug prices to a multiple of prices paid in peer nations — a policy known as international reference pricing or most-favored-nation pricing. An executive order to implement this for Medicare was pursued by the Trump administration, then withdrawn, then reconsidered; the Biden administration took a different approach through the IRA.
International reference pricing faces industry opposition based on arguments that it would reduce US investment in pharmaceutical innovation and that the lower prices in other countries exist because of different regulatory environments, not just negotiation. The debate over how much innovation the current US pricing system finances versus how much it extracts is genuine and unresolved.
What is clear is that the international price gap is unsustainable politically and is driving multiple policy experiments that will progressively narrow the difference over the next decade.
What This Means for Patients
For patients, the near-term trajectory is mixed:
- Medicare beneficiaries will see direct savings on a growing list of negotiated drugs beginning in 2026.
- Biosimilar competition for major biologics will gradually produce affordable alternatives for patients in the conditions those drugs treat.
- The out-of-pocket cap introduced by the IRA ($2,000 per year for Medicare Part D beneficiaries beginning in 2025) provides meaningful protection for high users of specialty medications.
- Gene therapy access will remain challenging for years as payer frameworks develop.
- AI-driven drug discovery is a 5–15 year horizon story that may not affect pricing in the immediate term.
The systemic transformation of drug pricing is underway — incremental, contested at every step, and likely to accelerate. Patients who stay informed about their rights, compare options actively, and use available assistance programs will be best positioned to navigate the transition.
This guide is for educational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making changes to your medication regimen.